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On the Effect of Estrogen Receptor Agonists and Antagonists
on the Mouse Hair Follicle Cycle
To the Editor:
We were quite surprised to read the Letter to the Editor by Stenn et
al in the Journal of Investigative Dermatology (110:95, 1998), stating that
the estrogen receptor agonist, 17-β-estradiol, and the estrogen receptor
antagonist, ICI 182,780, failed to alter mouse hair cycling. This result
is surprising as we have reported that: (i) the topical application of 17-
β-estradiol arrests hair follicles in telogen, (ii) the topical application
of ICI 182,780 causes telogen follicles to enter anagen, and (iii) the
estrogen receptor is expressed in the nuclei of the dermal papilla cells
of the telogen follicle in CD-1 mice (Oh and Smart, 1996). In their
letter, Stenn et al stated that they ‘‘made a concentrated attempt in
two independent and widely separated laboratories to reproduce the
experiments as described.’’ They further indicated that they ‘‘treated
animals following the Oh/Smart protocol precisely’’ and both of their
studies failed to demonstrate any effect of the agonist or antagonist. It
was most unfortunate that we were not afforded an opportunity to
read and respond to this letter before its publication because it is
obvious that these investigators did not conduct their experiments as
we described. The most profound difference we noted was that they
used doses of 17-β-estradiol and ICI 182,780 that were 5000-fold
lower than the doses we used. Dr. Stenn has confirmed that both his
laboratory and Dr. Paus’s laboratory used a 10 nM dose, which is
5000-fold lower than the correct dose of 10 nmol per 200 µl of
acetone vehicle. This dose is clearly stated in our paper.
In addition, Stenn et al did not use the CD-1 strain of mice that
was used in our studies, but instead used C3H and C57BL/6 mice
because they have ‘‘found that careful hair cycle studies using a
nonpigmented animal such as the CD-1 mouse, are difficult to
interpret.’’ Many high quality, seminal hair follicle cycle studies have
been conducted in nonpigmented mice. While it is of interest to
determine the efficacy of 17-β-estradiol and ICI 182,780 in other
strains of mice, it is regrettable that CD-1 mice were omitted from
their experimental design. The inclusion of CD-1 mice as a positive
control would have allowed these investigators the chance to detect
their dose error, as a 5000-fold lower dose would not be effective in
altering the hair follicle cycle in CD-1 mice, thus indicating that
something was wrong. The use of the correct dose of 17-β-estradiol
and ICI 182,780 would alter the hair follicle cycle in CD-1 mice just
as we reported in our studies. Although we do not know if 17-β-
estradiol and ICI 182,780 will function in C3H and C57BL/6 mice
as they do in CD-1 mice, we do know that other strains of mice such
as SENCAR and TG.AC mice respond to 17-β-estradiol in a manner
similar to CD-1 mice (unpublished results). Experiments to examine
the efficacy of 17-β-estradiol and ICI 182,780 in C57BL/6 and C3H
mice are currently underway in our laboratory.
Addendum We have completed the experiments on the effect of
17-β-estradiol and ICI 182,780 on the hair follicle cycle in C3H and
C57BL/6 mice. Using the experimental conditions described in our
previous publication (Oh and Smart, 1996) we found that in both
C3H and C57BL/6 mice, ICI 182,780 caused telogen follicles to enter
anagen and 17-β-estradiol arrested the hair follicles in telogen. Thus,
if the correct dose (10 nmol per 200 µl acetone vehicle) of estrogen
agonist and antagonist are employed, these agents alter the hair follicle
cycle in C3H and C57BL/6 mice in a manner similar to that previously
described in CD-1 mice.
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Reply:
The experiments we reported in our letter were described as executed,
and the mouse strains investigated were chosen for the reasons stated.
The experiments were planned and conducted completely independent
of one another but, unfortunately, the same mistake was made in both
cases – the concentrations used were not as reported in the original
report. Although we take responsibility for this oversight, we also
recognize that the dosage listing is not entirely conventional to the
field. Before starting the repeat experiments we consulted several
independent researchers outside our respective laboratories; in all cases
the understood dosage was interpreted exactly as we had.
When we repeated the work using the twice weekly protocol and
the concentrations used originally by Oh and Smart (Proc Natl Acad
Sci 93:12525), β-estradiol did indeed inhibit the normal progression
of spontaneous anagen in pigmented mice (C57B16). From additional
and subsequent studies that we have since executed, we have learned
several important features about the role of estrogen receptor-mediated
signaling in murine hair growth control that we did not formerly
appreciate. We would hope to share these data in a future report.
We are indebted to Drs. Oh and Smart for calling our attention to
this interesting phenomenon and regret the confusion our mistake
might have caused.
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Note from the Editor: Due to an editorial office error, Drs. Smart
and Oh were not given a chance to reply to the original letter about
their paper by Drs. Stenn, Paus, and Filippi (J Invest Dermatol, 110:95,
1998). We apologize to all the authors for this mistake.
